CL2023001992A1 - Anticuerpos anti-n3pglu beta amiloide y usos de estos - Google Patents
Anticuerpos anti-n3pglu beta amiloide y usos de estosInfo
- Publication number
- CL2023001992A1 CL2023001992A1 CL2023001992A CL2023001992A CL2023001992A1 CL 2023001992 A1 CL2023001992 A1 CL 2023001992A1 CL 2023001992 A CL2023001992 A CL 2023001992A CL 2023001992 A CL2023001992 A CL 2023001992A CL 2023001992 A1 CL2023001992 A1 CL 2023001992A1
- Authority
- CL
- Chile
- Prior art keywords
- n3pglu
- relates
- antibodies
- beta amyloid
- amyloid antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135932P | 2021-01-11 | 2021-01-11 | |
| US202163155029P | 2021-03-01 | 2021-03-01 | |
| US202163160380P | 2021-03-12 | 2021-03-12 | |
| US202163192262P | 2021-05-24 | 2021-05-24 | |
| US202163227054P | 2021-07-29 | 2021-07-29 | |
| US202163277298P | 2021-11-09 | 2021-11-09 | |
| US202163284248P | 2021-11-30 | 2021-11-30 | |
| US202263296694P | 2022-01-05 | 2022-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001992A1 true CL2023001992A1 (es) | 2024-02-02 |
Family
ID=80123357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001992A CL2023001992A1 (es) | 2021-01-11 | 2023-07-06 | Anticuerpos anti-n3pglu beta amiloide y usos de estos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240010713A1 (https=) |
| EP (1) | EP4274611A1 (https=) |
| JP (2) | JP7676556B2 (https=) |
| KR (2) | KR20260047659A (https=) |
| AU (1) | AU2022206461B2 (https=) |
| CA (1) | CA3204444A1 (https=) |
| CL (1) | CL2023001992A1 (https=) |
| CO (1) | CO2023009089A2 (https=) |
| EC (1) | ECSP23051813A (https=) |
| IL (1) | IL304072A (https=) |
| MX (1) | MX2023008196A (https=) |
| PE (1) | PE20231748A1 (https=) |
| TW (1) | TWI843040B (https=) |
| WO (1) | WO2022150735A1 (https=) |
| ZA (1) | ZA202306180B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022307687A1 (en) * | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| WO2023039107A2 (en) | 2021-09-09 | 2023-03-16 | Alzpath, Inc. | Phospho-tau antibodies and methods of use |
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| KR20250107906A (ko) * | 2022-11-17 | 2025-07-14 | 일라이 릴리 앤드 캄파니 | 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도 |
| KR20250173598A (ko) * | 2023-03-16 | 2025-12-10 | 알즈패스, 인크. | 신경퇴행성 질환의 진단 및 치료 방법 |
| WO2025231343A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases |
| WO2025240435A1 (en) * | 2024-05-14 | 2025-11-20 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| SI1720909T1 (sl) | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| PL3042917T3 (pl) | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN107289872A (zh) | 2017-06-28 | 2017-10-24 | 京东方科技集团股份有限公司 | 测高装置 |
| KR102905634B1 (ko) | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
-
2022
- 2022-01-10 TW TW111101008A patent/TWI843040B/zh active
- 2022-01-11 IL IL304072A patent/IL304072A/en unknown
- 2022-01-11 KR KR1020267008447A patent/KR20260047659A/ko active Pending
- 2022-01-11 AU AU2022206461A patent/AU2022206461B2/en active Active
- 2022-01-11 CA CA3204444A patent/CA3204444A1/en active Pending
- 2022-01-11 WO PCT/US2022/011894 patent/WO2022150735A1/en not_active Ceased
- 2022-01-11 JP JP2023541749A patent/JP7676556B2/ja active Active
- 2022-01-11 US US18/260,125 patent/US20240010713A1/en active Pending
- 2022-01-11 EP EP22701816.5A patent/EP4274611A1/en active Pending
- 2022-01-11 KR KR1020237027055A patent/KR102942744B1/ko active Active
- 2022-01-11 MX MX2023008196A patent/MX2023008196A/es unknown
- 2022-01-11 PE PE2023002030A patent/PE20231748A1/es unknown
-
2023
- 2023-06-12 ZA ZA2023/06180A patent/ZA202306180B/en unknown
- 2023-07-06 CL CL2023001992A patent/CL2023001992A1/es unknown
- 2023-07-07 CO CONC2023/0009089A patent/CO2023009089A2/es unknown
- 2023-07-10 EC ECSENADI202351813A patent/ECSP23051813A/es unknown
-
2025
- 2025-04-30 JP JP2025075147A patent/JP2025131566A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI843040B (zh) | 2024-05-21 |
| AU2022206461A1 (en) | 2023-06-29 |
| ZA202306180B (en) | 2025-02-26 |
| PE20231748A1 (es) | 2023-11-06 |
| TW202243690A (zh) | 2022-11-16 |
| IL304072A (en) | 2023-08-01 |
| MX2023008196A (es) | 2023-07-18 |
| KR20260047659A (ko) | 2026-04-08 |
| CA3204444A1 (en) | 2022-07-14 |
| WO2022150735A1 (en) | 2022-07-14 |
| KR20230130695A (ko) | 2023-09-12 |
| EP4274611A1 (en) | 2023-11-15 |
| CO2023009089A2 (es) | 2023-09-29 |
| KR102942744B1 (ko) | 2026-03-23 |
| JP7676556B2 (ja) | 2025-05-14 |
| US20240010713A1 (en) | 2024-01-11 |
| JP2025131566A (ja) | 2025-09-09 |
| JP2024503025A (ja) | 2024-01-24 |
| AU2022206461B2 (en) | 2026-02-05 |
| ECSP23051813A (es) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001992A1 (es) | Anticuerpos anti-n3pglu beta amiloide y usos de estos | |
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| Guo et al. | Electroacupuncture Improves Memory and Protects Neurons by Regulation of the Autophagy Pathway in a Rat Model of Alzheimer—s Disease | |
| MX2018012221A (es) | Metodos para tratar hiperlipidemia con un inhibidor de proteina tipo angiopoyetina 8 y un inhibidor de proteina tipo angiopoyetina 3. | |
| AR100772A1 (es) | Métodos para aumentar la inhibición tónica y tratar el insomnio secundario | |
| BR112023016319A2 (pt) | Anticorpos anti-beta amiloide e usos dos mesmos | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| CL2023001580A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| EP4438048A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES | |
| BR112023021235A2 (pt) | Formas cocristalinas de um inibidor da tirosina quinase de bruton | |
| EP4522772A4 (en) | TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4 | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| RU2019110264A (ru) | Циклическое соединение | |
| Shahsavand-Ananloo et al. | Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder. | |
| DOP2024000203A (es) | Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos | |
| EP4356916A4 (en) | Pharmaceutical composition for alleviating or treating sequelae of cerebral infarction | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| Sivolap | Serotonin neurotrasmission and treatment options for depression | |
| BR112018072164A2 (pt) | composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição | |
| Bano et al. | Effectiveness of melatonin supplementation in preventing cognitive decline among older adults with sleep disorders: a narrative review | |
| Poojary et al. | Acupressure–a review with a current and future prospective in dentistry | |
| AR125062A1 (es) | ANTICUERPOS ANTI-b AMILOIDE Y SUS USOS |